Core Viewpoint - The company, Stone Pharmaceutical Group, announced the purchase of a total of 504,000 shares under its share award plan, which will be held in trust for the benefit of selected participants [1] Group 1 - The shares will be purchased on October 15, 2025, by a trustee according to the terms and conditions of the share award plan [1] - The purchased shares will be held in trust for the benefit of selected participants [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 於2025年10月15日，受託人根據該計劃之條款及條件在市場上購買合共504,000股本公司股 份，並為獲選參與者之利益以信託方式持有該等股份。受託人於2025年10月15日所購買及 以信託方式持有之股份詳情如下： | 所購買股份總數： | 504,000股股份 | | --- | --- | | 所購買股份佔目前已發行股份總數百分比： | 約0.004 % | | 每股平均價格： | 約8.8948港元 | | 所購買股份之總代價： | 約4,483,000港元 | | 受託人所持股份結餘： | 109,504,000股股份 | 董 事 會 將 不 時 檢 討 ， 並 全 權 酌 情 決 定 擬 根 據 該 計 劃 授 予 獲 選 參 與 者 其 認 為 適 合 之 股 份 數 目，以及繼續從市場購買之股份數目。 石 藥 集 團 有 ...

Core Viewpoint - The innovative drug sector experienced a significant rally, with the innovative drug index rising by 2.35% as of the midday close on October 15, 2025, driven by strong performances from various companies [1][2]. Group 1: Market Performance - The innovative drug index (886015.TI) closed at 1366.835, reflecting a gain of 2.35%, equivalent to an increase of 31.422 points [2]. - Notable stock performances included Guangshentang, which surged by 20% to 122.65, and several other companies such as Shutaishen and Anglikang, which saw gains of 14.4% and 10.01%, respectively [2][3]. Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) conference is set to take place from October 17 to 21, 2025, in Berlin, Germany, where significant clinical research results and data are expected to be disclosed [3][4]. Group 3: Business Development Opportunities - There is growing market anticipation for the release of clinical data from domestic innovative drugs and business development (BD) collaborations, with 83 overseas BD transactions recorded in the first eight months of 2025, totaling 845 billion yuan, marking a 62.81% increase compared to the entire year of 2024 [4]. Group 4: Company Earnings Forecast - Several innovative drug companies are expected to report strong earnings for the third quarter of 2025, with Shengnuo Bio projecting a net profit of 114 million to 140 million yuan, representing a year-on-year increase of 100.53% to 145.10% [5]. - Boteng Co. anticipates a net profit of 73.2 million to 88.2 million yuan, indicating a turnaround from losses, driven by a 17% to 21% increase in revenue [5]. Group 5: Industry Outlook - Analysts express optimism regarding the innovative drug sector, anticipating stabilization and rebound due to upcoming catalysts such as BD and medical insurance negotiations [6]. - Long-term trends indicate that the Chinese pharmaceutical industry has transitioned to new growth drivers, particularly in innovative drugs, which are expected to significantly contribute to the growth of Chinese pharmaceutical companies over the next 5 to 10 years [7].

Core Viewpoint - New Nuo Wei is acquiring an additional 29% stake in Giant Stone Biopharmaceutical Co., Ltd. from its controlling shareholder, Enbi Pu Pharmaceutical Co., Ltd., which will increase its ownership to 80% after the transaction is completed [1][4]. Group 1: Acquisition Details - The acquisition price is set at 1.1 billion yuan, representing a premium of approximately 146% over the assessed value of Giant Stone Biopharmaceutical [6]. - New Nuo Wei previously acquired 51% of Giant Stone Biopharmaceutical for 1.871 billion yuan in early 2024, making it a controlling subsidiary [4][11]. - The transaction does not include any performance commitments from the seller [7]. Group 2: Financial Performance - Giant Stone Biopharmaceutical is currently operating at a loss, with losses of approximately 376 million yuan in the first half of 2025 [2][8]. - New Nuo Wei reported a loss of 2.7461 million yuan in the first half of 2025, marking its first mid-year loss since 2017 [7][9]. - The company's revenue for the first half of 2025 was 1.05 billion yuan, a year-on-year increase of 7.99% [7]. Group 3: Strategic Implications - The repeated acquisitions from the controlling shareholder indicate a strategic shift towards the innovative drug sector, as New Nuo Wei aims to enhance its market position [10][11]. - New Nuo Wei is planning to list in Hong Kong to support its global strategy and improve its international competitiveness [13]. - The company has faced challenges in its operational performance, raising questions about its ability to sustain normal operations post-acquisition [7][9].

Group 1 - Mindray Medical plans to issue H-shares and list on the Hong Kong Stock Exchange, aiming to broaden financing channels and enhance international influence for global business expansion and R&D [1] Group 2 - Shandong Buchang Pharmaceutical's investee company, Shiliu Yunyi, listed on NASDAQ using the VIE model, with an estimated market value of approximately $474 million on its first trading day, expected to positively impact Buchang's financials by 2025 [2] Group 3 - CSPC Pharmaceutical's subsidiary, CSPC Baike, received acceptance for the new drug application of Idaglutide α injection, which selectively activates GLP-1 receptors to aid weight loss and improve blood sugar and cardiovascular metrics, potentially capturing market share in the GLP-1 sector [3]

Core Viewpoint - The article discusses the recent acceptance of the new drug application for Idaglutide α injection by the China NMPA, developed by Shiyao Group's subsidiary, aimed at long-term weight management for overweight or obese adults [2][4]. Group 1: Drug Details - Idaglutide α injection is a recombinant human glucagon-like peptide-1 (hGLP-1) Fc fusion protein that requires weekly administration [2]. - The drug works by selectively binding and activating GLP-1 receptors, leading to appetite suppression and reduced food intake, thereby aiding in weight loss [4]. - It also lowers blood glucose levels in a glucose-dependent manner and improves cardiovascular and metabolic indicators [4]. Group 2: Clinical Trial Results - The new drug application is based on a pivotal Phase 3 clinical trial involving overweight adults with at least one weight-related comorbidity [4]. - Results showed that Idaglutide α significantly reduced body weight compared to a placebo, along with reductions in waist circumference, blood glucose, blood pressure, and blood lipids, providing cardiovascular and metabolic benefits [4]. - The drug demonstrated good safety and tolerability, with lower rates of gastrointestinal adverse events and treatment interruptions due to adverse events, and a quicker, simpler dose escalation scheme that reaches the target maintenance dose in just four weeks [4].

石药集团(01093)发布公告，于2025年10月14日，受托人根据该计划(限制性股份奖励计划)的条款及条件 在市场上购买合共600万股公司股份，并为获选参与者的利益以信托方式持有该等股份。 ...

智通财经APP讯，石药集团(01093)发布公告，于2025年10月14日，受托人根据该计划(限制性股份奖励 计划)的条款及条件在市场上购买合共600万股公司股份，并为获选参与者的利益以信托方式持有该等股 份。 ...

Core Viewpoint - The announcement indicates that the company, 石药集团 (Shijiazhuang Pharmaceutical Group), will purchase a total of 6 million shares of its own stock by October 14, 2025, for the benefit of selected participants through a trust arrangement [1] Group 1 - The company has appointed a trustee to execute the share purchase plan [1] - The shares will be held in trust for the benefit of selected participants [1] - The total number of shares to be purchased is 6 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 根據本公司股份獎勵計劃 在市場上購買股份 謹此 提述 石藥 集團 有限 公司（「本 公司」）於 2018 年8 月 20 日 有關 刊發 採納 本公 司限 制性 股份 獎勵計劃（「該計劃」）之公告（「該公告」）。誠如本公司日期為2024年5月21日之自願公告所披 露，該計劃之條款其後已作出修訂。除本公告另有界定外，本公告所用詞彙與該公告所界 定者具有相同涵義。 於2025年10月14日，受託人根據該計劃之條款及條件在市場上購買合共6,000,000股本公司 股份，並為獲選參與者之利益以信託方式持有該等股份。受託人於2025年10月14日所購買 及以信託方式持有之股份詳情如下： | 所購買股份總數： | 6,000,000股股份 | | --- | --- | | 所購買股份佔目前已發行股份總數百分比： | 約0.052 % | | 每股平均價格： | 約8.8436港元 | | 所購買股份之總代價： | ...